- Home
- MEGL vs GOVX Comparison
MEGL vs GOVX Comparison
Compare MEGL & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | GOVX |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | Hong Kong | United States |
| Employees | N/A | 19 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MEGL | GOVX |
|---|---|---|
| Price | $1.20 | $1.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 33.2K | ★ 524.2K |
| Earning Date | 04-10-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.12 |
| 52 Week High | $2.27 | $4.40 |
Technical Indicators
Market Signals| Indicator | MEGL | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 40.60 |
| Support Level | $1.16 | $1.17 |
| Resistance Level | $1.40 | $2.00 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 34.92 | 16.67 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The company's offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.